Trial Profile
A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GSK
- 06 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 12 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 May 2010 New trial record